Track topics on Twitter Track topics that are important to you
Heng Ren Investments of Boston believes Sinovac's management should raise its privatization offer for Sinovac by 75%: from $6.18 per share to $10.84. Just before management made its offer, Heng Ren says, Sinovac received China approval for its Hand, Foot and Mouth vaccine, a product with $400 million in potential revenues. Given that Sinovac. which is based in Beijing, posted $67 million in sales last year, the effect on Sinovac could be substantial. Heng Ren specializes in "orphan" China companies listed in the US and has a position in Sinovac. More details....
Stock Symbol: (NSDQ: SVA)
Share this with colleagues:
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...